Sernova Biotherapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	2020 - 2016
Net Income	-15.74	-32.19	-39	-24.42	-6.97	Upgrade
Depreciation & Amortization	0.34	0.54	0.45	0.44	0.27	Upgrade
Loss (Gain) From Sale of Assets	-0.06	-0.02	-	-	-	Upgrade
Stock-Based Compensation	2.51	1.75	3.9	7.45	0.22	Upgrade
Other Operating Activities	0.31	-0.13	-0.68	-0.84	-0.88	Upgrade
Change in Accounts Receivable	0.18	0.56	0.23	-0.2	-0.09	Upgrade
Change in Accounts Payable	1.54	10.59	4.75	3.31	0.46	Upgrade
Change in Other Net Operating Assets	0.02	0.01	0	-0.16	0.14	Upgrade
Operating Cash Flow	-10.91	-18.9	-30.34	-14.42	-6.84	Upgrade
Capital Expenditures	-	-	-0.1	-0.33	-0.02	Upgrade
Sale of Property, Plant & Equipment	0.02	-	-	-	-	Upgrade
Investment in Securities	-	11.08	34.92	-46	-	Upgrade
Other Investing Activities	-	0.04	-0.04	-0.01	-0.21	Upgrade
Investing Cash Flow	0.02	11.12	34.78	-46.34	-0.23	Upgrade
Long-Term Debt Issued	4.94	-	-	-	-	Upgrade
Long-Term Debt Repaid	-0.11	-0.17	-0.17	-0.17	-0.03	Upgrade
Net Debt Issued (Repaid)	4.82	-0.17	-0.17	-0.17	-0.03	Upgrade
Issuance of Common Stock	0.27	5.23	-	36.55	27.55	Upgrade
Other Financing Activities	0.05	0.01	0.68	0.28	3.47	Upgrade
Financing Cash Flow	5.14	5.07	0.5	36.66	31	Upgrade
Net Cash Flow	-5.75	-2.71	4.95	-24.1	23.92	Upgrade
Free Cash Flow	-10.91	-18.9	-30.44	-14.75	-6.86	Upgrade
Free Cash Flow Per Share	-0.03	-0.06	-0.10	-0.05	-0.03	Upgrade
Cash Income Tax Paid	0.01	-	-	-	-	Upgrade
Levered Free Cash Flow	-5.66	-6.65	-16.13	-5.56	-3.19	Upgrade
Unlevered Free Cash Flow	-5.19	-6.29	-16.11	-5.53	-3.18	Upgrade
Change in Working Capital	1.74	11.16	4.99	2.95	0.52	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.